The global Orally Disintegrating Tablet Excipient market was valued at US$ 15720 million in 2019 and is expected to reach US$ 20060 million by the end of 2026, growing at a CAGR of 3.5% during 2021-2026.
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications.An excipient is a pharmacologically inert adhesive substance used to bind the contents of a pill or tablet. This type of tablet separates in the mouth in contact with saliva, making it easy for a person to swallow the tablet without drinking water.
McePharma (Vivesa holding) was the global greatest company in Orally Disintegrating Tablet Excipient industry, with the revenue market Share of 3.5% in 2018, followed by BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical.
Global Orally Disintegrating Tablet Excipient Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Orally Disintegrating Tablet Excipient Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, McePharma (Vivesa holding), Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Type
Segment by Application
- Anti-Psychotics Drug
- Anti-Epileptics Drug
Table of Content:
1 Orally Disintegrating Tablet Excipient Market Overview
2 Orally Disintegrating Tablet Excipient Market Competition by Manufacturers
3 Orally Disintegrating Tablet Excipient Retrospective Market Scenario by Region
4 Global Orally Disintegrating Tablet Excipient Historic Market Analysis by Type
5 Global Orally Disintegrating Tablet Excipient Historic Market Analysis by Application
6 Key Companies Profiled
7 Orally Disintegrating Tablet Excipient Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Orally Disintegrating Tablet Excipient Market Dynamics
10 Global Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta